Health Care

Insider buying spurs optimism as Anavex’s CFO and CEO buy options amid FDA dialogue on blarcamesine—high‑risk biotech, high‑reward potential.

Accuray insider activity shows senior execs selling vested RSUs for liquidity while buying shares for upside, reflecting confidence in a profitable transformation plan.

Insightful look at Innovative Eyewear’s insider buying—buy low, sell high moves by execs reveal confidence amid market volatility.

BioCryst insider Dullinger’s large, conservative stake shows confidence amid executive sales, volatility, and cash‑flow challenges—watch key milestones for value.

Recursion Pharmaceuticals CSO David Hallett keeps 287k shares, showing confidence in its AI drug‑discovery platform despite volatile stock price.

Insightful look at AnaptysBio insider trades shows leadership confidence while aligning R&D, AI, and value‑based care strategies to secure future reimbursement and growth.

Ardelyx insider buy by Chief Patient Officer Laura Williams shows confidence amid social‑media buzz and a bullish pipeline for IBSRELA and XPHOZAH, yet option sales signal risk‑aware management.

Apellis insider buy: Watson David O. snaps up 888 shares at $14.95 amid bullish trend, signaling confidence ahead of J.P. Morgan Healthcare Conference.

Merck’s takeover of Cidara shows how a holding company can align post‑merger stakes, cut SEC reporting, and lock in a $221.50 cash payout—insights for investors, biotech funds and pharma players.

Joshua Levine holds 25,000 shares of EDAP TMS SA—an indicator of insider confidence amid a rally and a potential sign of future growth for the minimally invasive ultrasound company.